{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:52:27Z","timestamp":1791935547256,"version":"4.3.4"},"reference-count":23,"publisher":"American Veterinary Medical Association (AVMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To evaluate the safety and efficacy of a vaccine containing plasmid DNA with an insert encoding human tyrosinase (ie, huTyr vaccine) as adjunctive treatment for oral malignant melanoma (MM) in dogs.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u2014111 dogs (58 prospectively enrolled in a multicenter clinical trial and 53 historical controls) with stage II or III oral MM (modified World Health Organization staging scale, I to IV) in which locoregional disease control was achieved.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u201458 dogs received an initial series of 4 injections of huTyr vaccine (102 \u03bcg of DNA\/injection) administered transdermally by use of a needle-free IM vaccination device. Dogs were monitored for adverse reactions. Surviving dogs received booster injections at 6-month intervals thereafter. Survival time for vaccinates was compared with that of historical control dogs via Kaplan-Meier survival analysis for the outcome of death.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Kaplan-Meier analysis of survival time until death attributable to MM was determined to be significantly improved for dogs that received the huTyr vaccine, compared with that of historical controls. However, median survival time could not be determined for vaccinates because &lt; 50% died of MM before the end of the observation period. No systemic reactions requiring veterinary intervention were associated with vaccination. Local reactions were primarily limited to acute wheal or hematoma formation, mild signs of pain at the injection site, and postvaccination bruising.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Results support the safety and efficacy of the huTyr DNA vaccine in dogs as adjunctive treatment for oral MM.<\/jats:p>\n<jats:p><jats:bold>Impact for Human Medicine<\/jats:bold>\u2014Response to DNA vaccination in dogs with oral MM may be useful in development of plasmid DNA vaccination protocols for human patients with similar disease.<\/jats:p>","DOI":"10.2460\/ajvr.72.12.1631","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T19:52:22Z","timestamp":1322682742000},"page":"1631-1638","source":"Crossref","is-referenced-by-count":201,"title":["Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor"],"prefix":"10.2460","volume":"72","author":[{"given":"Deborah A.","family":"Grosenbaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Timothy","family":"Leard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karri","family":"Meleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Susaneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika K.","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Leibman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribeth H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene D.","family":"Kurzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Corynebacterium parvum. Cancer Invest","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3109\/07357908609017520","article-title":"Canine oral melanoma: comparison of surgery versus surgery plus","volume":"4","author":"MacEwen","year":"1986"},{"key":"ref2","series-title":"dog. J Am Anim Hosp Assoc","doi-asserted-by":"publisher","first-page":"294","DOI":"10.5326\/0390294","article-title":"Combined dorsolateral and intraoral approach for the resection of tumors of the maxilla in the","volume":"39","author":"Lascelles","year":"2003"},{"key":"ref3","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.2460\/javma.2001.218.1444","article-title":"Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989\u20132000)","volume":"218","author":"Rassnick","year":"2001"},{"key":"ref4","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2460\/javma.2004.224.388","article-title":"Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.","volume":"224","author":"Boria","year":"2004"},{"key":"ref5","series-title":"Vet Radiol Ultrasound","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1740-8261.2003.tb00468.x","article-title":"A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation.","volume":"44","author":"Proulx","year":"2003"},{"key":"ref6","series-title":"Clin Cancer Res","first-page":"4249","article-title":"Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.","volume":"5","author":"MacEwen","year":"1999"},{"key":"ref7","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/030098587901600103","article-title":"Prognosis after surgical excision of canine melanomas.","volume":"16","author":"Bostock","year":"1979"},{"key":"ref8","series-title":"J Am Vet Med Assoc","first-page":"580","article-title":"Prognostic criteria for dogs with oral melanoma.","volume":"178","author":"Harvey","year":"1981"},{"key":"ref9","series-title":"Cancer Ther","first-page":"817","article-title":"Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma.","volume":"6","author":"Bergman","year":"2008"},{"key":"ref10","series-title":"Cancer Immun","first-page":"8","article-title":"Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.","volume":"6","author":"Liao","year":"2006"},{"key":"ref11","series-title":"Clin Cancer Res","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.","volume":"9","author":"Bergman","year":"2003"},{"key":"ref12","series-title":"J Immunol","first-page":"5820","article-title":"A role for a melanosome transport signal in accessing the MHC Class II presentation pathway and in eliciting CD4+ T cell responses.","volume":"163","author":"Wang","year":"1999"},{"key":"ref13","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.vaccine.2008.01.059","article-title":"Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFN\u03b3 T cell responses in the dog.","volume":"26","author":"Goubier","year":"2008"},{"key":"ref14","series-title":"J Clin Invest","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1172\/JCI4004","article-title":"Tumor immunity and autoimmunity induced by immunization with homologous DNA.","volume":"102","author":"Weber","year":"1998"},{"key":"ref15","series-title":"J Exp Med","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.190.11.1717","article-title":"Coupling and uncoupling of tumor immunity and autoimmunity.","volume":"190","author":"Bowne","year":"1999"},{"key":"ref16","series-title":"Vaccine","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","article-title":"Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.","volume":"24","author":"Bergman","year":"2006"},{"key":"ref17","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1200\/JCO.2009.25.5489","article-title":"Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.","volume":"28","author":"Tang","year":"2010"},{"key":"ref18","article-title":"Guidance for industry\u2014E10 choice of control group and related issues in clinical trials. May 2001"},{"key":"ref19","series-title":"Clin Trials","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1740774506070654","article-title":"Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm phase II design.","volume":"3","author":"Taylor","year":"2006"},{"key":"ref20","series-title":"Mol Ther","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/sj.mt.6300290","article-title":"Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.","volume":"15","author":"Wolchok","year":"2007"},{"key":"ref21","series-title":"Cancer Immun","first-page":"5","article-title":"Safety and immunogenicity of a human and mouse gp 100 DNA vaccine in a phase I trial of patients with melanoma.","volume":"9","author":"Yuan","year":"2009"},{"key":"ref22","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.","volume":"15","author":"London","year":"2009"},{"key":"ref23","series-title":"Top Companion Anim Med","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.tcam.2009.06.001","article-title":"Cancer immunotherapy.","volume":"24","author":"Bergman","year":"2009"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/72\/12\/ajvr.72.12.1631.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/72\/12\/ajvr.72.12.1631.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/72\/12\/ajvr.72.12.1631.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:26:16Z","timestamp":1741350376000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/72\/12\/ajvr.72.12.1631.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.72.12.1631","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}